Next Article in Journal
Proteomic Analysis of Whole Human Saliva Detects Enhanced Expression of Interleukin-1 Receptor Antagonist, Thioredoxin and Lipocalin-1 in Cigarette Smokers Compared to Non-Smokers
Next Article in Special Issue
Neuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia
Previous Article in Journal
Comparison of the Phenolic Content and Antioxidant Activities of Apocynum venetum L. (Luo-Bu-Ma) and Two of Its Alternative Species
Previous Article in Special Issue
Nutraceutical Antioxidants as Novel Neuroprotective Agents
Int. J. Mol. Sci. 2010, 11(11), 4465-4487; doi:10.3390/ijms11114465

Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease

1,* , 2, 2, 1, 1, 1, 1, 1, 1, 1, 3 and 4
Received: 20 September 2010 / Revised: 22 October 2010 / Accepted: 27 October 2010 / Published: 9 November 2010
(This article belongs to the Special Issue Neuroprotective Strategies (special issue))
View Full-Text   |   Download PDF [1454 KB, uploaded 19 June 2014]   |   Browse Figures


Previously, we have found that mildronate [3-(2,2,2-trimethylhydrazinium) propionate dihydrate], a small molecule with charged nitrogen and oxygen atoms, protects mitochondrial metabolism that is altered by inhibitors of complex I and has neuroprotective effects in an azidothymidine-neurotoxicity mouse model. In the present study, we investigated the effects of mildronate in a rat model of Parkinson’s disease (PD) that was generated via a unilateral intrastriatal injection of the neurotoxin 6-hydroxydopamine (6‑OHDA). We assessed the expression of cell biomarkers that are involved in signaling cascades and provide neural and glial integration: the neuronal marker TH (tyrosine hydroxylase); ubiquitin (a regulatory peptide involved in the ubiquitin-proteasome degradation system); Notch-3 (a marker of progenitor cells); IBA-1 (a marker of microglial cells); glial fibrillary acidic protein, GFAP (a marker of astrocytes); and inducible nitric oxide synthase, iNOS (a marker of inflammation). The data show that in the 6-OHDA-lesioned striatum, mildronate completely prevented the loss of TH, stimulated Notch-3 expression and decreased the expression of ubiquitin, GFAP and iNOS. These results provide evidence for the ability of mildronate to control the expression of an array of cellular proteins and, thus, impart multi-faceted homeostatic mechanisms in neurons and glial cells in a rat model of PD. We suggest that the use of mildronate provides a protective effect during the early stages of PD that can delay or halt the progression of this neurodegenerative disease.
Keywords: Parkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small molecule Parkinson’s disease; 6-OHDA model; neuroimmunological biomarkers; mildronate; small molecule
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Klusa, V.Z.; Isajevs, S.; Svirina, D.; Pupure, J.; Beitnere, U.; Rumaks, J.; Svirskis, S.; Jansone, B.; Dzirkale, Z.; Muceniece, R.; Kalvinsh, I.; Vinters, H.V. Neuroprotective Properties of Mildronate, a Small Molecule, in a Rat Model of Parkinson’s Disease. Int. J. Mol. Sci. 2010, 11, 4465-4487.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert